The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Open accessAbstract
Strategies for unlocking immunosuppression in the tumor microenvironment have been investigated to overcome resistance to first-generation immune checkpoint blockade with anti- programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) agents. Indoleamine 2,3-dioxygenase (IDO) 1, an enzyme catabolizing tryptophan to kynurenine, creates an immunosuppressive environment in preclinical studies. Early phase clinical trials investigating inhibition of IDO1, especially together with checkpoint blockade, provided promising results. Unfortunately, the phase 3 trial of the IDO1 inhibitor epacadostat combined with the PD-1 inhibitor pembrolizumab did not show clinical benefit when compared with pembrolizumab monotherapy in patients with advanced malignant melanoma, which dampened enthusiasm for IDO inhibitors. Even so, several molecules, such as the aryl hydrocarbon receptor and tryptophan 2,3-dioxygenase, were reported as additional potential targets for the modulation of the tryptophan pathway, which might enhance clinical effectiveness. Furthermore, the combination of IDO pathway blockade with agents inhibiting other signals, such as those generated by PIK3CA mutations that may accompany IDO1 upregulation, may be a novel way to enhance activity. Importantly, IDO1 expression level varies by tumor type and among patients with the same tumor type, suggesting that patient selection based on expression levels of IDO1 may be warranted in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 707
Self-citationNguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq024 · Cited by 634
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.038 · Cited by 559
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Liu, Y., Liang, X., Dong, W., Fang, Y., Lv, J., Zhang, T., Fiskesund, R., Xie, J., Liu, J., Yin, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.005 · Cited by 535
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Campesato, L. F., Budhu, S., Tchaicha, J., Weng, C.-H., Gigoux, M., Cohen, I. J., Redmond, D., Mangarin, L., Pourpe, S., Liu, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17750-z · Cited by 516
Quintana, F. J., Murugaiyan, G., Farez, M. F., Mitsdoerffer, M., Tukpah, A.-M., Burns, E. J., & Weiner, H. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009201107 · Cited by 428
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1637 · Cited by 322
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294
Kato, S., Kim, K. H., Lim, H. J., Boichard, A., Nikanjam, M., Weihe, E., Kuo, D. J., Eskander, R. N., Goodman, A., Galanina, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18613-3 · Cited by 293
Self-citationJung, K. H., LoRusso, P., Burris, H., Gordon, M., Bang, Y.-J., Hellmann, M. D., Cervantes, A., Ochoa de Olza, M., Marabelle, A., Hodi, F. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2740 · Cited by 275
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., Nakamura, Y., Inui, N., Nakamura, H., & Chida, K. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.001 · Cited by 261
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 248
Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A., Nagasaka, T., Takikawa, O., & Kikkawa, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4144 · Cited by 239
Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebaek, E., Donia, M., Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01544-x · Cited by 211
Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients
Weinlich, G., Murr, C., Richardsen, L., Winkler, C., & Fuchs, D. (2007) · Dermatology · doi:10.1159/000096906 · Cited by 197
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033635 · Cited by 175
Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174
Hennequart, M., Pilotte, L., Cane, S., Hoffmann, D., Stroobant, V., Plaen, E. D., & Eynde, B. J. V. D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0400 · Cited by 171
Nakamura, T., Shima, T., Saeki, A., Hidaka, T., Nakashima, A., Takikawa, O., & Saito, S. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00470.x · Cited by 166
Nayak-Kapoor, A., Hao, Z., Sadek, R., Dobbins, R., Marshall, L., Vahanian, N. N., Jay Ramsey, W., Kennedy, E., Mautino, M. R., Link, C. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0351-9 · Cited by 160
Hsu, Y.-L., Hung, J.-Y., Chiang, S.-Y., Jian, S.-F., Wu, C.-Y., Lin, Y.-S., Tsai, Y.-M., Chou, S.-H., Tsai, M.-J., & Kuo, P.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.8488 · Cited by 158
Li, Q., Harden, J. L., Anderson, C. D., & Egilmez, N. K. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502615 · Cited by 153
Witkiewicz, A., Williams, T. K., Cozzitorto, J. A., Durkan, B., Showalter, S. L., Yeo, C. J., & Brody, J. R. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.014 · Cited by 150
Lowe, M. M., Mold, J. E., Kanwar, B., Huang, Y., Louie, A., Pollastri, M. P., Wang, C., Patel, G., Franks, D. G., Schlezinger, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087877 · Cited by 136
Greene, L. I., Bruno, T. C., Christenson, J. L., D’Alessandro, A., Culp‐Hill, R., Torkko, K. C., Borges, V. F., Slansky, J. E., & Richer, J. K. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0362 · Cited by 133
Iversen, T. Z., Engell-Noerregaard, L., Ellebæk, E., Andersen, R. S., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1560 · Cited by 129
Zhai, L., Bell, A., Ladomersky, E., Lauing, K. L., Bollu, L., Nguyen, B., Genet, M., Kim, M., Chen, P., Mi, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1392 · Cited by 129
Hollingshead, B. D., Beischlag, T. V., DiNatale, B. C., Ramadoss, P., & Perdew, G. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6168 · Cited by 128
Pantouris, G., Serys, M., Yuasa, H. J., Ball, H. J., & Mowat, C. G. (2014) · Amino Acids · doi:10.1007/s00726-014-1766-3 · Cited by 127
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Witkiewicz, A. K., Costantino, C. L., Metz, R. A., Muller, A. J., Prendergast, G. C., Yeo, C. J., & Brody, J. R. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.12.018 · Cited by 126
Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., Agdashian, D., Zhang, Q., Korangy, F., & Greten, T. F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2190-4 · Cited by 119
Qin, R., Zhao, C., Wang, C., Xu, W., Zhao, J., Lin, Y., Yuan, Y., Lin, P., Li, Y., Zhao, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002840 · Cited by 118
Corre, S., Tardif, N., Mouchet, N., Leclair, H. M., Boussemart, L., Gautron, A., Bachelot, L., Perrot, A., Soshilov, A. A., Rogiers, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06951-2 · Cited by 103
Kristeleit, R. S., Давиденко, І., Shirinkin, V., El-Khouly, F., Bondarenko, I., Goodheart, M. J., Горбунова, В. А., Penning, C. A., Shi, J. G., Liu, X., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.005 · Cited by 102
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
Amobi, A. E., Muthuswamy, R., Battaglia, S., Yu, H., Liu, T., Wang, J., Putluri, V., Singh, P. K., Qian, F., Huang, R.-Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678999 · Cited by 96
Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
Mancuso, R., Hernis, A., Agostini, S., Rovaris, M., Caputo, D., Fuchs, D., & Clerici, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130715 · Cited by 94
Sicklick, J. K., Kato, S., Okamura, R., Patel, H., Nikanjam, M., Fanta, P. T., Hahn, M. E., De, P. K., Williams, C. B., Guido, J., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00969-w · Cited by 94
Self-citationIDO1 is an Integral Mediator of Inflammatory Neovascularization
Mondal, A., Smith, C., DuHadaway, J. B., Sutanto‐Ward, E., Prendergast, G. C., Bravo‐Nuevo, A., & Muller, A. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.013 · Cited by 92
Siu, L. L., Gelmon, K. A., Chu, Q. S.-C., Pachynski, R. K., Alese, O. B., Basciano, P. A., Walker, J., Mitra, P., Zhu, L., Phillips, P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct116 · Cited by 88
Gibney, G. T., Hamid, O., Lutzky, J., Olszanski, A. J., Mitchell, T. C., Gajewski, T. F., Chmielowski, B., Hanks, B. A., Zhao, Y., Newton, R. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0562-8 · Cited by 88
Gomes, B., Driessens, G., Bartlett, D. W., Cai, D., Cauwenberghs, S., Crosignani, S., Dalvie, D., Denies, S., Dillon, C. P., Fantin, V. R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1104 · Cited by 85
Schafer, C. C., Wang, Y., Hough, K. P., Sawant, A., Grant, S. C., Thannickal, V. J., Zmijewski, J. W., Ponnazhagan, S., & Deshane, J. S. (2016) · Oncotarget · doi:10.18632/oncotarget.12249 · Cited by 84
Conroy, J. M., Pabla, S., Glenn, S. T., Burgher, B., Nesline, M., Papanicolau‐Sengos, A., Andreas, J., Giamo, V., Lenzo, F. L., Hyland, F. C. L., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.10.001 · Cited by 80
Self-citationEndogenous Indole Pyruvate Pathway for Tryptophan Metabolism Mediated by IL4I1
Zhang, X., Gan, M., Li, J., Li, H., Su, M., Tan, D., Wang, S., Jia, M., Zhang, L., & Chen, G. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c03735 · Cited by 76
Kenison, J. E., Wang, Z., Yang, K., Snyder, M., Quintana, F. J., & Sherr, D. H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012692118 · Cited by 74
Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype
DiNatale, B. C., Smith, K. M., John, K., Gowda, K., Amin, S., & Perdew, G. H. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0216 · Cited by 73
Liang, H., Li, T., Fang, X., Xing, Z., Zhang, S., Shi, L., Li, W., Guo, L., Kuang, C., Liu, H., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.012 · Cited by 69
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 68
Self-citationYamamoto, T., Hatabayashi, K., Arita, M., Yajima, N., Takenaka, C., Suzuki, T., Takahashi, M., Oshima, Y., Hara, K., Kagawa, K., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw3306 · Cited by 67
Maria, N. I., van Helden-Meeuwsen, C. G., Brkić, Z., Paulissen, S. M. J., Steenwijk, E. C., Dalm, V. A. S. H., van Daele, P. L. A., van Hagen, P. M., Kroese, F. G. M., van Roon, J. A. G., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39629 · Cited by 66
Balog, A., Lin, T.-A., Maley, D., Gullo-Brown, J. L., Kandoussi, E. H., Zeng, J., & Hunt, J. T. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0251 · Cited by 63
Reardon, D. A., Desjardins, A., Rixe, O., Cloughesy, T. F., Alekar, S., Williams, J. H., Li, R., Taylor, C. T., & Lassman, A. B. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00950-1 · Cited by 61
Ochs, K., Ott, M., Rauschenbach, K. J., Deumelandt, K., Sahm, F., Opitz, C. A., von Deimling, A., Wick, W., & Platten, M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13503 · Cited by 55
Bjoern, J., Iversen, T. Z., Nitschke, N. J., Andersen, M. H., & Svane, I. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.010 · Cited by 55
Soliman, H. H., Khambati, F. A., Han, H. S., Ismail-Khan, R. R., Bui, M. M., Sullivan, D. M., & Antonia, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24118 · Cited by 54
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
DAUD, A. I., Saleh, M. N., Hu, J. S., Bleeker, J. S., Riese, M. J., Meier, R., Zhou, L., Serbest, G., & Lewis, K. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9511 · Cited by 52
Winters, M., DuHadaway, J. B., Pham, K., Lewis-Ballester, A., Badir, S., Wai, J., Sheikh, E., Yeh, S., Prendergast, G. C., Muller, A. J., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.010 · Cited by 52
Mariotti, V., Han, H. S., Ismail-Khan, R. R., Tang, S., Dillon, P. M., Montero, A. J., Poklepovic, A. S., Melin, S. A., Ibrahim, N. K., Kennedy, E. P., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5572 · Cited by 52
TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway
Li, L., Wang, T., Li, S., Chen, Z., Wu, J., Cao, W., Wo, Q., Qin, X., & Xu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.562823 · Cited by 51
Kjeldsen, J. W., Iversen, T. Z., Engell-Noerregaard, L., Mellemgaard, A., Andersen, M. H., & Svane, I. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02145 · Cited by 49
Naing, A., Eder, J. P., Piha-Paul, S. A., Gimmi, C. D., Hussey, E. K., Zhang, S., Hildebrand, V., Hosagrahara, V. P., Habermehl, C., Moisan, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000870 · Cited by 46
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
Röhrig, U. F., Majjigapu, S. R., Caldelari, D., Dilek, N., Reichenbach, P., Ascenção, K., Irving, M. B., Coukos, G., Vogel, P., Zoete, V., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.031 · Cited by 42
Zakharia, Y., Rixe, O., Ward, J. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9512 · Cited by 42
Hellmann, M. D., Gettinger, S. N., Chow, L. Q. M., Gordon, M. S., Awad, M. M., Cha, E., Gong, X., Zhou, G., Walker, C., Leopold, L. H., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32951 · Cited by 41
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Newton, R. C., Schaub, R., Maleski, J. E., Leopold, L. H., & Gajewski, T. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3025 · Cited by 40
Missing the target in cancer therapy
Adashek, J. J., Goloubev, A., Kato, S., & Kurzrock, R. (2021) · Nature Cancer · doi:10.1038/s43018-021-00204-w · Cited by 40
Self-citationKotecki, N., Vuagnat, P., O’Neil, B. H., Jalal, S. I., Rottey, S., Prenen, H., Benhadji, K. A., Xia, M., Szpurka, A. M., Saha, A., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000368 · Cited by 40
Bahary, N., Wang-Gillam, A., Haraldsdottir, S., Somer, B. G., Lee, J. S., O'Rourke, M. A., Nayak-Kapoor, A., Beatty, G. L., Liu, M., Delman, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4015 · Cited by 39
Discovery of indoximod prodrugs and characterization of clinical candidate NLG802
Kumar, S., Jaipuri, F. A., Waldo, J. P., Potturi, H., Marcinowicz, A., Adams, J., Allen, C. V., Zhuang, H., Vahanian, N. N., Link, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112373 · Cited by 39
Targeting the Aryl Hydrocarbon Receptor Signaling Pathway in Breast Cancer Development
Vogel, C. F. A., Lazennec, G., Kado, S. Y., Dahlem, C., He, Y., Castañeda, A. R., Ishihara, Y., Vogeley, C., Rossi, A., Haarmann‐Stemmann, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625346 · Cited by 37
Zahm, C. D., Johnson, L. E., & McNeel, D. G. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02394-w · Cited by 35
Sumitomo, M., Takahara, K., Zennami, K., Nagakawa, T., Maeda, Y., Shiogama, K., Yamamoto, Y., Muto, Y., Nukaya, T., Takenaka, M., et al. (2021) · Cancer Science · doi:10.1111/cas.14797 · Cited by 33
Dey, S., Mondal, A., DuHadaway, J. B., Sutanto‐Ward, E., Laury‐Kleintop, L. D., Thomas, S., Prendergast, G. C., Mandik‐Nayak, L., & Muller, A. J. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0226 · Cited by 31
Naing, A., Powderly, J. D., Falchook, G. S., Creelan, B., Nemunaitis, J. J., Lutzky, J., Diab, A. K., Wang, J. S.-Z., Laing, N. M., Niewood, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct177 · Cited by 26
The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis
Shibata, Y., Hara, T., Nagano, J., Nakamura, N., Ohno, T., Ninomiya, S., Ito, H., Tanaka, T., Saito, K., Seishima, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146279 · Cited by 25
Zhang, R., Li, T., Wang, W., Gan, W., Lv, S., Zeng, Z., Hou, Y., Yan, Z., & Yang, M. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594098 · Cited by 23
Sieviläinen, M., Saavalainen, J., Awad, S. A., Salo, T. A., & Al‐Samadi, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812822 · Cited by 23
A phase I study of indoximod in combination with docetaxel in metastatic solid tumors.
Jackson, E., Dees, E. C., Kauh, J. S. W., Harvey, R. D., Neuger, A. M., Lush, R. M., Antonia, S. J., Minton, S. E., Ismail-Khan, R. R., Han, H. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3026 · Cited by 22
(2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0297-3 · Cited by 20
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance
Sandri, S., Watanabe, L. R. M., de Oliveira, E. A., Faião‐Flores, F., Migliorini, S., Tiago, M., Felipe-Silva, A., Vazquez, V. D. L., Souza, P. D. C., Consolaro, M. E. L., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104998 · Cited by 19
Meireson, A., Ferdinande, L., Haspeslagh, M., Hennart, B., Allorge, D., Ost, P., Sundahl, N., Spaas, M., Demeyer, A., & Brochez, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736498 · Cited by 19
Szeto, C. W., Kurzrock, R., Kato, S., Goloubev, A., Veerapaneni, S., Preble, A., Reddy, S. K., & Adashek, J. J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100396 · Cited by 16
Self-citationPrendergast, G. C., & Metz, R. A. (2012) · OncoImmunology · doi:10.4161/onci.21358 · Cited by 14
Gutcher, I., Kober, C., Roese, L., Roewe, J., Schmees, N., Prinz, F., Gorjánácz, M., Roehn, U., Bader, B., Irlbacher, H., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-1288 · Cited by 13
Doi, T., Fujiwara, Y., Shitara, K., Shimizu, T., Yonemori, K., Matsubara, N., Ohno, I., Kogawa, T., Naito, Y., Leopold, L. H., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00942-1 · Cited by 12
Self-citationde Iudicibus, R. C., Tomek, P., Palmer, B. D., Tijono, S., Flanagan, J. U., & Ching, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116160 · Cited by 12
Cited by
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Nanomaterials: Breaking through the bottleneck of tumor immunotherapy
Kang, Y., & Li, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123159 · Cited by 61
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
Metadata
- Authors
- Fujiwara, Y., Kato, S., Nesline, M. K., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 110
- Pages
- 102461
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W4293581628
- Cited by
- 304
- References
- 106
- FWCI
- 21.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.